Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Tapan M. Kadia"'
Autor:
Mary Ayres, Varsha Gandhi, William G. Wierda, Kumudha Balakrishnan, Michael J. Keating, Susan O'Brien, Jan A. Burger, Nitin Jain, Alessandra Ferrajoli, Jorge E. Cortes, Tapan M. Kadia, Francesco Paolo Tambaro
Publikováno v:
Oncotarget, vol 8, iss 13
Oncotarget
Oncotarget
Chemoimmunotherapy regimens have been the standard first-line therapy for patients with chronic lymphocytic leukemia (CLL). For young, fit patients the standard of care is combination of fludarabine, cyclophosphamide, and rituximab (FCR). Based on th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51ca38c7e53df4e060c881238cb5769a
https://escholarship.org/uc/item/55d8841w
https://escholarship.org/uc/item/55d8841w
Autor:
Gautam Borthakur, Naval Daver, Marina Konopleva, Rebecca Garris, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Deborah A. Thomas, Tapan M. Kadia, Susan O'Brien, Hagop M. Kantarjian, Jorge E. Cortes, Michael Rytting
Publikováno v:
Haematologica, vol 100, iss 5
We have previously reported on the efficacy and tolerability of hyper-CVAD regimen (cyclophosphamide, vincristine, Adriamycin, and dexamethasone) and imatinib followed by imatinib-based consolidation/maintenance therapy in 20 patients with newly diag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8006c36b7951f987c550f20b147fdcd0
https://escholarship.org/uc/item/8g27z7bb
https://escholarship.org/uc/item/8g27z7bb